Question 1

What is CYWC628?

Accepted Answer

CYWC628 is a Other.

Question 2

How often does CYWC628 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 11 articles.

Question 3

When was CYWC628 first tracked by Ergen?

Accepted Answer

First tracked on Jun 03, 2026.

Question 4

When was CYWC628 last mentioned in news?

Accepted Answer

Last active on Jun 16, 2026.

Question 5

What is CYWC628's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is CYWC628 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving CYWC628?

Accepted Answer

FibroBiologics Doses First CYWC628 Patients (Jun 03, 2026, 11 articles).

Question 8

How did the "FibroBiologics Doses First CYWC628 Patients" event impact CYWC628?

Accepted Answer

CYWC628 is an investigational allogeneic fibroblast cell-based therapy developed by FibroBiologics for wound healing, specifically diabetic foot ulcers. The advancement to patient dosing in a Phase 1/2 clinical trial is a crucial step in its development and potential market entry.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.